Onco Actu du 27 mars 2019

	1. BIOLOGIE
Protein ‘spat out’ by cancer cells promotes tumour growth [University of Bradford] The tiny pieces of protein are taken up by the other cells, provoking changes that promote tumour growth and – the researchers believe - help the cancer hide from the body’s immune system. The process has been captured for the first time on video by researchers at the University of Bradford and University of Surrey.
	1.1 BIOLOGIE - GÈNES
New Human Genome Reference Projects Combine Long Nanopore Reads, Other Data Types [Genome Web] Two ongoing efforts to produce new human genome assemblies are combining ultra-long nanopore reads with other types of sequencing and mapping data to generate gapless or near-gapless assemblies that can serve as reference genomes for future studies.
	1.4 BIOLOGIE - TECHNOS
Cellular censuses to guide cancer care [Nature] “We just got a whole bunch of new toys,” she says. “Now we need to work on developing more computational methods and collecting more patient data from more cohorts to understand what these toys can tell us.”
	2.6 ETIOLOGIE - ENVIRONNEMENT
U.S. jury to determine liability, damages in Roundup cancer trial [Reuters] Jurors will now decide whether Roundup was defectively designed, whether Monsanto acted negligently, and if it failed to warn consumers of Roundup’s cancer risks. If jurors find the company liable, they can award compensatory and punitive damages.
	5. TRAITEMENTS
New Therapy Targets Painful Side Effect of Cancer Treatment [University of Connecticut] Starting out in liquid form, the anesthetic turns to a gel when it comes into contact with the mouth and reaches the temperature of the human body. The medication can then stay in place on mouth sores. Since the UConn technology uses an anesthetic that is also more potent than lidocaine, the researchers expect it should relieve pain for about eight times as long as the standard mouth rinse, approximately four hours.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Tumor-Associated Immune Cells Hinder Frontline Chemotherapy Drug in Pancreatic Cancer [University of Michigan] After genetically and pharmacologically depleting the number of tumor-associated macrophages in mouse models, the team showed that the tumors were less resistant to gemcitabine — offering a clue toward potentially making patients’ tumors more responsive to chemotherapy.
	5.10 TRAITEMENTS - ESSAIS
Data suggest US, UK universities fall woefully short on reporting clinical trial results [EndPoints] The violators include some of the most active trial sponsors: For example the MD Anderson Cancer Center, which has only reported 77% of due trials, Mayo Clinic (42%), UC San Francisco (37%), New York University (21%), and Columbia University (17%).
Top US institutes still aren’t reporting clinical-trial results on time [Nature] US law requires researchers to post study findings on a public registry within a year of completion — or face heavy fines.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
10 Leading Immuno-Oncology Startups [Clinical OMICS] The following is a list of the Top 10 Immuno-Oncology Startups, which includes developers of cancer immunotherapies that have yet to reach the market, ranked by total capital raised through a combination of private financing and, for most of the companies listed, net proceeds from initial public offerings (IPOs).
Contending for CD47 throne, Arch Oncology scores $50M as it ramps up PhI studies [EndPoints] The big idea at Arch Oncology — popularized by the likes of Forty Seven and Boehringer Ingelheim — is to block the “don’t eat me” signal emitted by CD47 and thereby help immune cells spot and destroy cancer.
	5.2 PHARMA
iTeos brings on Sanofi cancer VP as CMO as it wades deeper into the clinic [Fierce Biotech] Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new chief medical officer. The hire comes after the company raised $75 million last June to bring two of its assets to the clinic—an adenosine A2A antagonist and an anti-TIGIT antibody—as well as help fund an expansion to new offices in Cambridge, Massachusetts.
After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint [Fierce Biotech] Despite trying to dig out the positive, Can-Fite shares were halved premarket on the NYSE, before settling at being around 33% down. It was down 26% on its local stock exchange in Tel Aviv.
Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma [Johnson & Johnson] First DARZALEX combination treatment regimen being pursued in the frontline setting for transplant eligible patients with multiple myeloma.
Israeli biotech flunks PhII liver cancer study, but it insists drug Can-Fite disease in subset of patients [EndPoints] The drug, namodenoson, was being tested in a 78-patient Phase II study in patients with advanced liver cancer in patients with underlying cirrhosis, whose disease had progressed despite firstline treatment with Bayer’s Nexavar.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Questions & answers: EU actions to prevent medicine shortages due to Brexit [EMA] The document underlines that Brexit will not impact the safety of medicines, nor the way they are evaluated. EMA and the Member States will continue to monitor the safety and efficacy of medicines without any changes.
	6.1 OBSERVATION
Children’s chances of surviving cancer less than 30% in poor nations – study [The Guardian] Stark differences revealed in five-year survival rates between rich and low- and middle-income countries
	6.11 PATIENTS
Doctors share story of daughter’s treatment for leukemia [Stanford Medicine] When your child develops cancer, the first thing you think is, 'What did I do wrong? What could I have done differently?' Now, when Erin meets a parent of a child with cancer, she said she makes a point of communicating to them that they didn't do anything wrong and to let go of any feelings of guilt they may have.
	6.2 IMPLANTS MAMMAIRES
Women need better information on breast implants, panel says [Washington Post] Members of a Food and Drug Administration advisory committee scrutinizing the safety of breast implants urged the agency on Tuesday to take steps to ensure that patients have a clearer understanding.
	6.6 PUBLICATIONS
As Elsevier Falters, Wiley Succeeds in Open-Access Deal Making [The Scientist] The divergent strategies of scholarly publishers to forge licensing agreements with libraries are yielding different results.
	6.7 DMP, BIG DATA & APPLIS
The promise of real-world data [Nature] We discussed with five scientists what the sources and roles of real-world evidence are, how we can use such data in clinical trials and how these data can be converted into useful information that can impact patient management and regulatory decisions in oncology.
	6.7.3 DMP
New Rules Will Ease Patients’ Access To Electronic Medical Records, Senate Panel Says [KHN] Alexander said HHS believes the new rules should give more than 125 million patients easier access to their own records in an electronic format.